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ABSTRACT 
The experience with liver transplantation at the University 
of Pittsburgh for hepatic cancer is presented. The results for 
"usual" and .. incidental" tumors are compared. Based upon this 
experience, a revision of current recommendations for 
transplantation consideration is suggested. Finally, the concept 
of a team approach to this problem and its implementation at the 
University of Pittsburgh is described. 
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Hepatic cancer is an unusual tumor in the united States. 
However, it is a common cause of death in the more populous area 
of the world such as southeast Asia and southern Africa. In such 
areas, it is the most common cause of death among young adult 
working males between the ages of 30 and 50 years (1). 
In the united States, primary hepatic cancer has an estimated 
annual incidence of 13,600 cases (Table 1). Because hepatic cancer 
is not responsive to current modes of systemic cancer chemotherapy, 
because it is not particularly radiosensitive, and because most of 
all it often presents late in its natural history or in 
individuals, who are either not operable or who are unresectable, 
its annual prevalence and its annual incidence are almost the same. 
CUrrently, surgical excision of hepatic cancer is the only 
therapy capable of curing the disease (2). Surgical procedures 
that have been utilized to accomplish such cures range from 
subsegmental resections of small lesions to maj or hepatic 
resections such as right and left trisegmentectomy (3-6). The 
larger of these procedures may have an operative mortality as high 
as 40%. Unfortunately, most individuals with primary hepatic 
cancer are either not operable or if operable, are not resectable 
at the time of initial presentation because of the presence of 
associated cirrhosis or local nodal or even more distant metastasis 
(7-12) • Thus, currently less than 35% of explored cases are 
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resectable and less than 20% of explored cases are resected 
"totally" at the time of their initial surgical procedure. 
An extension of the surgical approach to hepatic cancer is the 
application of orthotopic liver transplantation to the treatment 
of this difficult disease (7-12). The resection in such cases is 
typically extended beyond that of a "simple" liver transplant to 
include resection of the gastro-hepatic and gastro-duodenal 
ligaments, skeletalization of all of the vascula.r structures 
leading to the liver as well as the common bile duct and resection 
of the bile duct as it crosses behind the duodenum with the 
creation of a roux-en-Y choledochojejunostomy. Despite such 
extensive surgery, the results with liver transplantation for 
hepatocellular carcinoma have been rather poor. Pichlmayr, who 
utilized the data available in the European Liver Transplant 
Registry, reported a 30% survival at 2 years for patients 
transplanted for hepatocellular carcinoma. A more recent series 
from Pittsburgh reports 1, 3 and 5 year survival rates for liver 
transplantation performed for hepatocellular carcinoma of 64%, 37% 
and 37% respectively (14). Thus, despite careful selection of 
patients and the application of more extensive surgical resections 
both in Europe and the United states, only a third of the patients 
operated upon for hepatocellular cancer are cured (survive > 5 
years) . 
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The situation is quite different, however, in cases of 
incidental hepatocellular carcinoma (2,15,16). Such cases consist 
of tumors that are recognized incidentally as a consequence of a 
workup directed toward some other goal; such as determining the 
candidacy for liver transplantation of an individual with liver 
disease. These incidental tumors are detected as a consequence of 
a computerized tomography scan or ultrasound examination or as a 
result of a regular quarterly or semiannual monitoring of a 
cirrhotic patient for the development of a hepatocellular 
carcinoma. In contrast to what is seen for cases transplanted for 
clinically evident hepatic cancer, the experience with liver 
transplantation for incidental lesions has been excellent with 2 
and 5 year survival rates of 90% (2). 
In general such tumors are small, less than 5 cm in diameter, 
have a capsule or at least a pseudocapsule of surrounding non-
neoplastic hepatocytes; importantly, such tumors usually lack 
either nodal involvement or vascular invasion. 
These characteristics stand in contrast to the current 
generally accepted parameters that are used to identify cases for 
possible liver transplantation for hepatocellular carcinoma which 
are the following: 
1) the presence of cirrhosis; 
2) multi focal disease; 
3) a central location of the tumor near or involving the 
porta; and 
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4) extensive disease involving more than one lobe. 
The factors currently recognized as identifying good and poor risk 
patients for a surgical cure are summarized in Table 2. 
The failure of liver transplantation to yield long term 
survival when performed for hepatocellular carcinoma is a direct 
consequence of the failure of current diagnostic modalities to be 
able to identify micrometastasis beyond the confines of the 
extended hepatectomy performed as part of the transplant procedure 
performed for hepatocellular carcinoma. Because of this failure 
and because of the remarkable success experienced with liver 
transplantation for incidental tumors, one has to question the 
validity of current guidelines for considering liver 
transplantation in cases with hepatocellular carcinoma. Based upon 
the experience with incidental cancer, it is quite clear that the 
surgical goal of excising all neoplastic disease is predictably 
achievable only if the tumor is small and asymptomatic (i. e. 
incidental) (2). Therefore, the current practice of offering liver 
transplantation for large symptomatic tumors appears unsound, and 
attention might be better directed toward transplantation being 
offered for small tumors that are identified as incidental lesions 
during the routine followup of patients with cirrhosis. 
Such an approach should result in a high cure rate for both 
the hepatic cancer and the underlying hepatic disease. Table 3 
shows the range of underlying liver diseases for which non-
fibrolamellar hepatic cancer has been the indication for liver 
transplantation at the University of Pittsburgh. Fifty-two percent 
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of the patients with hepatic cancer seen at this institution for 
possible transplantation have had chronic hepatitis B. An 
additional 22.5\ have had either cryptogenic or putative NANB 
chronic hepatitis and cirrhosis. Seventeen and a half percent 
(17.5%) have had an underlying metabolic liver disease. Thus 
serial screening of patients with advanced hepatic disease as a 
result of chronic viral infection or metabolic disease would have 
identified 94% of the cases at an early state at which time their 
survival could have been improved from its current 37% at 5 years 
to 90%, nearly a three fold improvement. Thus it is quite clear 
that the responsibility of improving the current results resides 
with physicians rather than with the transplant surgeons. Surgeons 
have already proven their skill and can cure hepatic cancer if 
appropriate patients are referred to them. Early detection of HCC 
in an individual with advanced liver disease as a result of serial 
ultrasound and serologic investigations (e.g. a fetoprotein and 
descarboxyprothrombin) by specialist physicians in hepatology 
should markedly increase the identification of "incidental lesions" 
where the rate of failure to cure with liver transplantation 
approaches the reported operative mortality rate experienced with 
a major hepatic resection. With a more appropriate referral of 
early cases, even those greater than 5 cm but less than 10 cm in 
diameter, which are single lesions involving only 1 hepatic lobe, 
coupled with the utilization of adjuvant chemotherapy with or 
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without associated radiotherapy should result in improved results 
manifested as longer survivals and qreater cure rates than 
heretofore have been possible. 
with these concepts in mind, a combined transplantation 
oncology program has been developed at the University of 
Pittsburgh. This program consists of individuals with expertise 
in surgery, medical oncology, radiology, radiation therapy and 
hepatology. The experience of this group with hepatic cancer is 
still preliminary but appears quite promising as is shown in Table 
4. 
The experience with liver transplantation for cholangiolar 
carcinoma has been even poorer than that experienced with 
hepatocellular carcinoma. This is true whether or not such tumors 
are divided into those that are bile duct cancers (extrahepatic, 
large duct, central lesions) or cholangiocarcinomas (intrahepatic, 
small duct, peripheral lesions). The 1 year survival for such 
lesions is 25% and declines further to less than 20% at 2 years. 
These lesions occur frequently in individuals with primary 
sclerosing cholangitis (PSC). Statistically, one of every 10 
individuals transplanted for PSC will be found to have a 
cholangiolar carcinoma. Despite the well recognized predilection 
of individuals with PSC to develop cholangiolar carcinoma, no good 
method for early detection of such cancers exists. These tumors 
are difficult to identify with current imaging techniques except 
when there is a high grade biliary obstruction which occurs late 
in their natural history. Moreover, it is frequently difficult, 
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if not impossible, to distinguish obstructing malignant from 
obstructing non-malignant lesions in PSC. Bile duct cytology has 
been utilized and found to be a specific but not a very sensitive 
means of distinguishing between the two. In addition to being more 
difficult to identify, once identified, most cases have nodal 
involvement which prohibits any chance of a surgical cure. Worse 
yet, because this tumor is neither radiosensitive nor responsive 
to available chemotherapy regimens; adjuvant methods have not 
enhanced the outcome experienced with surgical resection alone. 
Despite such grim facts, the oncology program within the 
transplant service at the University of Pittsburgh has developed 
therapeutic protocols for these patients. The early experience 
with cholangiolar carcinoma by this group is shown in Table 5. 
In summary, hepatic cancer is most likely to be an increasing 
indication for liver transplantation as a consequence of better 
survival as a result of earlier detection and referral for 
transplantation by physicians adjuvant chemotherapy. 
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'l'ABLB 1 
BBPA'l'ZC CANCER AND BBV 
Annual Incidence 13,600 cases (USA) 
HBV is responsible for 80% of the cases worldwide 
HBsAg positive individuals have a 200-300 fold increased 
risk for hepatocellular cancer as compared to controls 
Age at time of infection determines carrier risk 
~UR% if S10 years 
SlOt if ~OM years 
TABLE 2 
FACTORS THAT AFFECT SURVIVAL OF PATIENTS WITH 
HBPATIC CANCER TREATED WITH 
LIVER TRANSPLANTATION 
Factors That Improve 
prognosis 
Factors That Reduce 
Prognosis 
1) incidental lesion 1) symptoms of cancer 
2) < 5 cm diameter 2) vascular invasion 
3) single lesion 3) multiple lesions 
4) presence of a "capsule" 4) bile duct origin 
5) liver cell origin 
TABLB 3 
OOEXXSTXHG LXVER DXSEASE XH CASES TRANSPLANTED 
FOR HEPATOCELLULAR CARCXHOMA 
Liver Disease 
Hepatitis B 
Non A Non B Hepatitis 
Cryptogenic Cirrhosis 
Metabolic Liver Disease 
hemochromatosis 
Q, antitrypsin deficiency 
tyrosinemia 
Percent 
52.0 
5.0 
12.5 
17.5 
TABLE 4 
LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA 
Problem 1. High regional and distant recurrence rates. 
2. Patients presenting with hepatic decompensation 
who cannot tolerate i/hepatic artery 
chemotherapy. 
strategy 1. OLTx 
Results 
2. Post-transplant systemic adjuvant chemotherapy 
with 5-FU/folinic acid/alpha-interferon. 
# Patients treated since 10/89 
# Patients with recurrence 
6 
1 (17%) 
Problem: 
strategy 
Results 
TABLE 5 
CBOLANGIOCARCINOMA 
Post-transplant regional recurrences. 
Pre-transplant radiotherapy with 
chemosensitization. 
# patients accrued since 10/89 
5 liver transplants 
3 cluster-liver transplants 
Total n = 8 
No recurrence so far 
